Phospho-tau217 has emerged as an excellent marker of the presence of amyloid pathology in the brain, but for markers of neurofibrillary tangles, fragments of tau’s microtubule binding region have a ...

Back in mid-June, Alzforum reported on how the AD research field was being buffeted by cuts in funding to the National Institutes of Health (Jun 2025 news; Jun 2025 news). At the time, scientists felt ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

The Dominantly Inherited Alzheimer Network has been at the vanguard of AD immunotherapy development, launching the first secondary and primary prevention trials, as well as the first study of ...

Lithium is one of the oldest drugs in psychiatric medicine, commonly prescribed for bipolar disorder. Now, a study in the August 6 Nature lays out a new case for the potential use of this metal ...

Statins do not help prevent Alzheimer’s disease, but another cholesterol-controlling drug just might. Obicetrapib blocks cholesteryl esters being transferred from the “good” high-density lipoproteins ...

Computational biology has put the human brain vasculature in its crosshairs. On July 23 in Neuron, scientists led by Andrew Yang, University of California, San Francisco, report a multiomic approach ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

The first direct-to-consumer Alzheimer’s disease blood test has arrived. Quest Diagnostics, a worldwide diagnostic service headquartered in Secaucus, New Jersey, announced on July 31 that it would ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...